Use of the serum free light chain assay in assessment of response to therapy in multiple myeloma: Validation of recently proposed response criteria in a prospective clinical trial of lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.

被引：0

作者：

Kumar, S

Gertz, MA

Hayman, SR

Lacy, MQ

Dispenzieri, A

Zeldenrust, SR

Lust, JA

Greipp, PR

Kyle, RA

Fonseca, R

Rajkumar, SV

机构：

[1] Mayo Clin, Scottsdale, AZ USA

[2] Mayo Clin, Rochester, MN USA

来源：

BLOOD | 2005年 / 106卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3479

引用

页码：971A / 971A

页数：1

共 50 条

[31] Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma [J].

Fukushima, Toshihiro ;

Nakamura, Takuji ;

Iwao, Haruka ;

Umehara, Hisanori .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (10) :893-893

[32] Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial [J].

Landgren, Ola ;

Hultcrantz, Malin ;

Diamond, Benjamin ;

Lesokhin, Alexander M. ;

Mailankody, Sham ;

Hassoun, Hani ;

Tan, Carlyn ;

Shah, Urvi A. ;

Lu, Sydney X. ;

Salcedo, Meghan ;

Werner, Kelly ;

Rispoli, Jenna ;

Caple, Julia ;

Sams, Allison ;

Verducci, Dennis ;

Jones, Katie ;

Concepcion, Isabel ;

Ciardello, Amanda ;

Chansakul, Aisara ;

Schlossman, Julia ;

Tavitian, Elizabet ;

Shekarkhand, Tala ;

Harrison, Angela ;

Piacentini, Casey ;

Rustad, Even H. ;

Yellapantula, Venkata ;

Maclaughlan, Kylee ;

Maura, Francesco ;

Landau, Heather J. ;

Scordo, Michael ;

Chung, David J. ;

Shah, Gunjan ;

Lahoud, Oscar B. ;

Thoren, Katie ;

Murata, Kazunori ;

Ramanathan, Lakshmi ;

Arcila, Maria E. ;

Ho, Caleb ;

Roshal, Mikhail ;

Dogan, Ahmet ;

Derkach, Andriy ;

Giralt, Sergio A. ;

Korde, Neha .

JAMA ONCOLOGY, 2021, 7 (06) :862-868

[33] Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial [J].

Rajkumar, S. Vincent ;

Jacobus, Susanna ;

Callander, Natalie S. ;

Fonseca, Rafael ;

Vesole, David H. ;

Williams, Michael E. ;

Abonour, Rafat ;

Siegel, David S. ;

Katz, Michael ;

Greipp, Philip R. .

LANCET ONCOLOGY, 2010, 11 (01) :29-37

[34] Utility of serum free light chain ratio in response definition in patients with multiple myeloma [J].

Abdallah, Nadine ;

Kapoor, Prashant ;

Murray, David L. ;

Buadi, Francis K. ;

Dingli, David ;

Dispenzieri, Angela ;

Gertz, Morie A. ;

Go, Ronald S. ;

Gonsalves, Wilson I. ;

Hayman, Suzanne R. ;

Kourelis, Taxiarchis V. ;

Lacy, Martha Q. ;

Leung, Nelson ;

Lust, John A. ;

Muchtar, Eli ;

Warsame, Rahma ;

Kyle, Robert A. ;

Rajkumar, S. Vincent ;

Kumar, Shaji K. .

BLOOD ADVANCES, 2020, 4 (02) :322-326

[35] VALUE OF THE FREE LIGHT CHAIN ANALYSIS IN THE CLINICAL EVALUATION OF RESPONSE IN MULTIPLE MYELOMA PATIENTS RECEIVING ANTI-MYELOMA THERAPY [J].

Hansen, T. ;

Nielsen, C. ;

Pedersen, T. ;

Ambi, B. ;

Abildgaard, N. .

HAEMATOLOGICA, 2012, 97 :624-625

[36] A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma. [J].

Rajkumar, S. V. ;

Hussein, M. ;

Catalano, J. ;

Jedrzejcak, W. ;

Sirkovich, S. ;

Olesnyckyj, M. ;

Yu, Z. ;

Knight, R. ;

Zeldis, J. B. ;

Blade, J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :426S-426S

[37] Speed and duration of response and patient reportsEndpoints (PROs) of daratumumab plus lenalidomide and dexamethasone therapy vs lenalidomide and dexamethasone in non-transplantable patients with newly diagnosed multiple myeloma: Phase 3 MAIA study [J].

Goldschmidt, H. ;

Facon, T. ;

Kumar, S. K. ;

Plesner, T. ;

Moreau, P. ;

Bahlis, N. ;

O'Dwyer, M. ;

Perrot, A. ;

Venner, C. P. ;

Weisel, K. ;

Mace, J. R. ;

Raje, N. ;

Tiab, M. ;

Macro, M. ;

Frenzel, L. ;

Leleu, X. ;

Pei, H. ;

Borgsten, F. ;

Usmani, S. Z. .

ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) :90-91

[38] Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) [J].

Bhutani, Manisha ;

Robinson, Myra ;

Atrash, Shebli ;

Paul, Barry ;

Pineda-Roman, Mauricio ;

Foureau, David ;

Varga, Cindy ;

Friend, Reed ;

Begic, Xhevahire ;

Norek, Sarah ;

Drennan, Tiffany ;

Anderson, Michelle B. ;

Symanowski, James ;

Voorhees, Peter M. ;

Usmani, Saad Z. .

BLOOD, 2023, 142

[39] Thalidomide, Intravenous Cyclophosphamide and Dexamethasone (ThaCyDex) in Newly Diagnosed Multiple Myeloma: Response to Therapy, Time to Progression and Survival [J].

Jezael Martinez-Rueda, Armando ;

Maria Armillas-Canseco, Flor ;

Olivas-Martinez, Antonio ;

Martinez-Banos, Deborah .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 :S239-S239

[40] Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma [J].

Tacchetti, Paola ;

Rocchi, Serena ;

Dozza, Luca ;

Zamagni, Elena ;

Caratozzolo, Isola ;

Rizzello, Ilaria ;

Fusco, Alessio ;

De Cicco, Gabriella ;

Pantani, Lucia ;

Mancuso, Katia ;

Terragna, Carolina ;

Testoni, Nicoletta ;

Zinzani, Pier Luigi Luigi ;

Cavo, Michele .

BLOOD, 2019, 134

← 1 2 3 4 5 →